<DOC>
	<DOCNO>NCT02267213</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy TLC388 ( Lipotecan ) second line treatment subject advance Hepatocellular Carcinoma .</brief_summary>
	<brief_title>Efficacy Safety Study TLC388 Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Radiological diagnosis hepatic tumor ( ) contrastenhanced study Subjects advance HCC eligible surgical resection locoregional therapy . Subjects sorafenib treatment failure due sorafenib intolerance radiographic PD ( per RECIST v1.1 ) . Prior sorafenib use ≥ 400 mg/day least 14 day . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Child Pugh Score ≤ 6 ; A life expectancy least 12 week Subjects receive systemic target therapy systemic chemotherapy sorafenib treatment HCC . Subjects receive sorafenib within 2 week prior initiation treatment dose , sorafenibrelated toxicity yet resolve grade 1 baseline . Subjects undergone liver transplantation surgery . Major surgery within 4 week prior initiation treatment dose ( exclude implantation intravenous infusion device ) . Percutaneous liver puncture within 2 week prior initiation treatment dose .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>